Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
- Written by PR Newswire
 |
- Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping.
- Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development.
SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ) today...
